Bharat Parenterals Ltd — Important, 12-11-2025: Company Update

Bharat Parenterals shared its investor presentation for the quarter and half-year, showing standalone Q2FY26 revenue at ₹41.7 Cr and PAT at ₹2.7 Cr. Performance was impacted by deferred export shipments and production upgrades, with management expecting volumes to normalize. A major highlight is Innoxel Lifesciences receiving USFDA approval (EIR) for its Baroda facility, clearing the path for US market supply. Innoxel also finalized seven new strategic deals worth USD 1.85 million. Consolidated revenue stood at ₹64.6 Cr, with a PAT loss of ₹8.6 Cr, an improvement year-on-year.